bluuebunny/crossref_metadata_2025_split huggingface dataset:
Dysphagia After Cervical Spinal Surgery: An Assessment of Incidence and Predisposing Factors
Authors: Eriksson Sven E. , Ohde Jane , Zheng Ping , Sarici Inanc S. , Jobe Blair A. , Ayazi Shahin 
Published: October 2024

Background: Dysphagia is common following cervical spinal surgery (CSS) yet reported incidence and risk factors are highly heterogeneous. This case-control study aimed to determine the incidence of dysphagia after CSS and identify its predisposing factors. Methods: Records of 1199 patients who underwent CSS over a 2-year period at our center were reviewed. Patients with postoperative dysphagia and an equal number of randomly selected patients without dysphagia were included for analysis. Demographic, clinical, intraoperative, and perioperative factors were compared using univariate followed by multivariable logistic regression analysis. Results: The study population consisted of 94 (7.8%) patients with dysphagia and 94 controls. Patients with postoperative dysphagia were older [mean (SD) 60.7(12) vs 54.7(12), P = .002] and more likely to have preoperative dysphagia (16% vs 0%, P < .001). No other demographic or clinical factors were significant. Mid-level (C3-4, C4-5) (66% vs 48%, P = .018) and multilevel surgeries (67% vs 50%, P = .026) were associated with dysphagia. No other intraoperative factors were significant. The presence of any (abscess, dehiscence, hematoma, CSF leak, prevertebral edema, esophageal, or vocal cord injury) perioperative complication (20% vs 3.2%, P < .001) was associated with dysphagia, with dehiscence (6.5% vs 0%, P = .029) and hematoma (6.5% vs 0%, P = .029) showing the strongest association. Multivariable analysis identified age ≥70 [OR (95% CI): 2.8 (1-7), P = .031] and any perioperative complication [OR (95% CI): 6.7 (2-25), P = .004] as independent predictors of dysphagia. Conclusion: The incidence of dysphagia after cervical spine surgery is 7.8%. The risk of postoperative dysphagia is 6.7-times higher in those with perioperative complications and 2.8-times higher in patients over 70.
Spring-Assisted Cranioplasty in Unicoronal Synostosis: Analysis of Outcomes
Authors: Frommer Sarah Anne , Combs Patrick Duffy , Tyler-Kabara Elizabeth Christine , Kelley Patrick Kevin 
Published: October 2024

Background: Spring-assisted cranioplasty and successful long-term outcomes for sagittal synostosis has been well described in recent literature. However, there is a paucity of data regarding the application of springs to unicoronal synostosis. Unicoronal synostosis (UCS) presents unique challenges in its causation of skull base scoliosis and orbital asymmetry. Many surgeons feel that the fronto-orbital advancement and vault remodeling is the most effective and reliable strategy to counteract these changes. Here we present our experience and outcomes with spring cranioplasty for unicoronal synostosis. Materials and methods: A retrospective review of non-syndromic unicoronal synostosis patients undergoing spring-assisted cranioplasty was performed. Preoperative and postoperative intracranial volume (ICV), orbital volume (OV), orbital height (OH), orbital width (OW), midface twist (MFT), and skull-base twist (SBT) were measured from DICOM CT data. Analysis was performed with Materialize software (Leuven, Belgium). Paired t-tests were performed using Excel. Results: Ten patients (5 females, 5 males) had springs placed at 100.1 days (avg). Average ICV: preop: 608.2 ± 101.4 cc, postop: 995.2 ± 166.1 cc. Differences in orbital volume and height in the preop affected orbit versus non-affected orbit was significant ( P = .01, P ≤ .001 respectively) whereas no significant difference between the two sides postoperatively was observed ( P = .19, P = .58 respectively). Average preop MFT was 81.1 ± 2° and postop was 87.6 ± 2.6° and preop SBT was 171.9 ± 2.7° and postop was 177.6 ± 2.6°; both showing significant improvement after spring cranioplasty (both P ≤ .001). Conclusion: Our experience and early outcomes with spring cranioplasty for UCS demonstrates that when used in younger patients (<5 months) cranial springs can be a safe and effective strategy to minimize skull base scoliosis, facial scoliosis, and orbital asymmetry, as well as increase intracranial volume. Although long-term data needs to be assessed, we are optimistic that early correction of cranial base scoliosis will translate to stable results as patients reach dentoskeletal maturity.
Follicular lymphoma comprises germinal center–like and memory-like molecular subtypes with prognostic significance
Authors: Laurent Camille , Trisal Preeti , Tesson Bruno , Seth Sahil , Beyou Alicia , Roulland Sandrine , Lesne Bastien , Van Acker Nathalie , Cerapio Juan-Pablo , Chartier Loïc , Guille Arnaud , Stokes Matthew E. , Huang C. Chris , Huet Sarah , Gandhi Anita K. , Morschhauser Franck , Xerri Luc 
Published: October 2024

Abstract
A robust prognostic and biological classification for newly diagnosed follicular lymphoma (FL) using molecular profiling remains challenging. FL tumors from patients treated in the RELEVANCE trial with rituximab-chemotherapy (R-chemo) or rituximab-lenalidomide (R2) were analyzed using RNA sequencing, DNA sequencing, immunohistochemistry (IHC), and/or fluorescence in situ hybridization. Unsupervised gene clustering identified 2 gene expression signatures (GSs) enriched in normal memory (MEM) B cells and germinal center (GC) B-cell signals, respectively. These 2 GSs were combined into a 20-gene predictor (FL20) to classify patients into MEM-like (n = 160) or GC-like (n = 164) subtypes, which also displayed different mutational profiles. In the R-chemo arm, patients with MEM-like FL had significantly shorter progression-free survival (PFS) than patients with GC-like FL (hazard ratio [HR], 2.13; P = .0023). In the R2 arm, both subtypes had comparable PFS, demonstrating that R2 has a benefit over R-chemo for patients with MEM-like FL (HR, 0.54; P = .011). The prognostic value of FL20 was validated in an independent FL cohort with R-chemo treatment (GSE119214 [n = 137]). An IHC algorithm (FLcm) that used FOXP1, LMO2, CD22, and MUM1 antibodies was developed with significant prognostic correlation with FL20. These data indicate that FL tumors can be classified into MEM-like and GC-like subtypes that are biologically distinct and clinically different in their risk profile. The FLcm assay can be used in routine clinical practice to identify patients with MEM-like FL who might benefit from therapies other than R-chemo, such as the R2 combination. This trial was registered at www.clinicaltrials.gov as #NCT01476787 and #NCT01650701.
Cost-effectiveness of iptacopan for paroxysmal nocturnal hemoglobinuria
Authors: Ito Satoko , Chetlapalli Karthik , Wang Daniel , Potnis Kunal C. , Richmond Rhys , Krumholz Harlan M. , Lee Alfred I. , Cuker Adam , Goshua George 
Published: October 2024

Abstract
Iptacopan, a novel oral factor B inhibitor, recently obtained US Food and Drug Administration approval for treating paroxysmal nocturnal hemoglobinuria, a rare blood disorder characterized by persistent complement-mediated hemolytic anemia. The standard-of-care (SOC) has traditionally relied on complement C5 inhibitors eculizumab and ravulizumab, which are limited by persistent anemia from extravascular hemolysis and requirement for intravenous infusion. Recent publication of phase 3 studies in this arena reinforces iptacopan as an effective anticomplement monotherapy compared with SOC. Given ongoing price negotiations and limited literature showing its cost-ineffectiveness in the anti-C5–treated population, we conducted a comprehensive cost-effectiveness analysis of iptacopan monotherapy in anti-C5–treated patients from the societal perspective, as compared with C5 inhibition. The primary outcomes were the incremental net monetary benefit across a lifetime horizon and the cost-effective maximum monthly threshold price of iptacopan monotherapy compared with the SOC. The secondary outcome was time saved for patients and nurses with the use of oral iptacopan therapy. Iptacopan monotherapy and SOC accrued 12.6 and 10.8 quality-adjusted life-years at costs of $9.52 million and $13.5 million, respectively. Iptacopan monotherapy remained cost saving across extensive sensitivity and all scenario analyses, including alternative parameterization for anemia resolution and aggregated individual-level utilities and transition probability matrix. Across all probabilistic sensitivity analyses, iptacopan monotherapy was favored over SOC in 100% of 10 000 Monte Carlo iterations. Cost-saving thresholds for iptacopan vs anti-C5 are ∼1.1, 1.4, and 1.4 in Brazil, Japan, and the United States, respectively. Iptacopan monotherapy can improve quality-adjusted life expectancy for patients while saving health care costs across jurisdictions.
Social determinants of health affect disease severity among preschool children with sickle cell disease
Authors: Khan Hamda , Kang Guolian , Porter Jerlym S. , Ding Juan , Wang Winfred C. , Estepp Jeremie H. , Gurney James G. , Davis Robert , Hankins Jane S. , Hodges Jason R. 
Published: October 2024

Abstract
Individuals with sickle cell disease (SCD) face the burden of managing a lifelong chronic illness, increasing vulnerability to social determinants of health (SDoH). However, how SDoH contributes to health disparities is understudied. We hypothesized that preschool children with SCD living in poor neighborhoods with higher socio-economic distress would experience increased acute care utilization (ACU; described as emergency department visits plus hospitalizations) despite disease-modifying therapy. Participants' home addresses (aged 0-6 years) were mapped using census tract environmental data from the US Department of Agriculture Food Access Research Atlas. In multivariable analyses controlled for sickle genotype and disease-modifying therapies (hydroxyurea and chronic transfusion), SDoH indicators, that is, limited access to food, lack of vehicle, low income, and inadequate education, were associated with higher ACU. Living in households with children &gt;1 mile from a supermarket was associated with more hospitalizations (odds ratio [OR], 1.44; 95% confidence interval [CI], 1.13-1.85) and ACU (OR, 1.37; 95% CI, 1.06-1.80) among children with SCD (aged &lt;6 years). In households with at least 1 bachelor's degree, children with SCD experienced less ACU (OR, 0.67; 95% CI, 0.50-0.93) and hospitalizations (OR, 0.67; 95% CI, 0.49-0.92). Preschool children with SCD with limited access to food and transportation are at a higher risk of acute complications despite receiving free evidence-based therapy and social support. The family education level may have a protective effect. Although SDoH in crowded households and health care maintenance visits were not a focus of this study, future research should consider these factors. Understanding the SCD and SDoH association is crucial for directing resources to improve affected children's health.
Unbiased high-throughput screening of drug-repurposing libraries identifies small-molecule inhibitors of clot retraction
Authors: Buitrago Lorena , Menezes Miriam-Rose , Larson Chloe , Li Jihong , Kartika Thomas , Banerjee Priyam , Glickman Fraser , Coller Barry 
Published: October 2024

Abstract
Platelet clot retraction, the ultimate phase of platelet thrombus formation, is critical for clot stabilization. It requires functional αIIbβ3 receptors, fibrin, and the integrated actions of the actin-myosin contractile and cytoskeletal systems. Disturbances in clot retraction have been associated with both bleeding and thrombosis. We recently demonstrated that platelets treated with the αIIbβ3 antagonist peptide Arg-Gly-Asp-Trp, which eliminates fibrinogen-mediated platelet aggregation, are still able to retract clots. We have exploited this observation to develop an unbiased, functional high-throughput assay to identify small-molecule inhibitors of fibrin-mediated clot retraction adapted for a 384-well plate format. We tested 9710 compounds from drug-repurposing libraries (DRLs). These libraries contain compounds that are either US Food and Drug Administration approved or have undergone preclinical/clinical development. We identified 27 compounds from the Library of Pharmacologically Active Compounds library as inhibitors of clot retraction, of which 14 are known inhibitors of platelet function. From the DRLs, we identified 135 compounds (1.6% hit rate). After extensive curation, these compounds were categorized based on the activity of their reported target. Multiple kinase and phosphodiesterase inhibitors with known antiplatelet effects were identified, along with multiple deubiquitination and receptor inhibitors, as well as compounds that have not previously been reported to have antiplatelet activity. Studies of 1 of the deubiquitination inhibitors (degrasyn) suggest that its effects are downstream of thrombin-induced platelet-fibrinogen interactions and thus may permit the separation of platelet thrombin-induced aggregation-mediated events from clot retraction. Additional studies of the identified compounds may lead to novel mechanisms of inhibiting thrombosis.
Maintenance of hematopoietic stem cells by tyrosine-unphosphorylated STAT5 and JAK inhibition
Authors: Williams Matthew J. , Wang Xiaonan , Bastos Hugo P. , Grondys-Kotarba Gabriela , Wu Qin , Jin Shucheng , Johnson Carys , Mende Nicole , Calderbank Emily , Wantoch Michelle , Park Hyun Jung , Mantica Giovanna , Hannah Rebecca , Wilson Nicola K. , Pask Dean C. , Hamilton Tina L. , Kinston Sarah J. , Asby Ryan , Sneade Rachel , Baxter E. Joanna , Campbell Peter , Vassiliou George S. , Laurenti Elisa , Li Juan , Göttgens Berthold , Green Anthony R. 
Published: October 2024

Abstract
Adult hematopoietic stem cells (HSCs) are responsible for the lifelong production of blood and immune cells, a process regulated by extracellular cues, including cytokines. Many cytokines signal through the conserved Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway in which tyrosine-phosphorylated STATs (pSTATs) function as transcription factors. STAT5 is a pivotal downstream mediator of several cytokines known to regulate hematopoiesis, but its function in the HSC compartment remains poorly understood. In this study, we show that STAT5-deficient HSCs exhibit an unusual phenotype, including reduced multilineage repopulation and self-renewal, combined with reduced exit from quiescence and increased differentiation. This was driven not only by the loss of canonical pSTAT5 signaling, but also by the loss of distinct transcriptional functions mediated by STAT5 that lack canonical tyrosine phosphorylation (uSTAT5). Consistent with this concept, expression of an unphosphorylatable STAT5 mutant constrained wild-type HSC differentiation, promoted their maintenance, and upregulated transcriptional programs associated with quiescence and stemness. The JAK1/2 inhibitor, ruxolitinib, which increased the uSTAT5:pSTAT5 ratio, had similar effects on murine HSC function; it constrained HSC differentiation and proliferation, promoted HSC maintenance, and upregulated transcriptional programs associated with stemness. Ruxolitinib also enhanced serial replating of normal human hematopoietic stem and progenitor cells (HSPCs), calreticulin-mutant murine HSCs, and HSPCs obtained from patients with myelofibrosis. Our results therefore reveal a previously unrecognized interplay between pSTAT5 and uSTAT5 in the control of HSC function and highlight JAK inhibition as a potential strategy for enhancing HSC function during ex vivo culture. Increased levels of uSTAT5 may also contribute to the failure of JAK inhibitors to eradicate myeloproliferative neoplasms.
Incremental eligibility criteria for the BMT CTN 1507 haploidentical trial for children with sickle cell disease
Authors: John Tami D. , Walters Mark C. , Rangarajan Hemalatha G. , Rahim Mahvish Q. , McKinney Christopher , Bollard Catherine M. , Abusin Ghada , Eapen Mary , Kassim Adetola A. , DeBaun Michael R. 
Published: October 2024

Abstract
The Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 1507 leadership and the data safety monitoring board (DSMB) established incremental entry criteria for children aged 5 to 14.99 years with sickle cell disease (SCD) enrolling in a phase 2 trial of HLA-haploidentical hematopoietic stem cell transplantation. First, the enrollment was limited to overt stroke in the first 10 participants (stage 4). Subsequently, the DSMB reviewed the interim results and expanded the eligibility to include children with silent cerebral infarcts or abnormal transcranial Doppler velocities with magnetic resonance angiography–defined cerebral vasculopathy (stage 3). A third cohort was enrolled after the DSMB reviewed the clinical outcomes in these cumulative initial enrollments (n = 18) and additions were made to the entry criteria that included nonneurologic morbidities (stage 2). Added eligibility criteria included the following: (1) life-threatening acute chest syndrome requiring exchange transfusion; (2) right heart catheterization confirmed pulmonary hypertension; (3) persistent systemic hypertension despite maximum medical therapy; (4) acute pain despite maximum medical therapy in the absence of psychosocial factors and unmanaged asthma after adjudication; and (5) 2 major priapism episodes in 12 months or 3 in 24 months. Children with SCD who did not meet the criteria for stages 4, 3, and 2 were not eligible. To our knowledge, for the first time, we introduce a staged strategy for eligibility in a curative therapy trial for children with SCD concordant with 45 Code of Federal Regulations § 46.405(b). The research governance–mandated eligibility strategy used within the BMT CTN 1507 phase 2 study may apply to future pediatric SCD curative therapy trials. This trial was registered at www.ClinicalTrials.gov as #NCT032635590.
Sustained remission at long term follow-up in adolescents and young adults with chronic primary immune thrombocytopenia
Authors: Schifferli Alexandra , Le Gavrian Gautier , Aladjidi Nathalie , Moulis Guillaume , Godeau Bertrand , Leblanc Thierry , Héritier Sébastien , Fernandes Helder , Kühne Thomas 
Published: October 2024

Abstract
Adolescents and young adults (AYAs) with immune thrombocytopenia (ITP) exhibit distinct clinical features and needs, defying categorization as either adults or children. Previous findings revealed a 50% risk of chronic disease at 12 months, yet the long-term course remains unclear. This study aimed to delineate the clinical and laboratory characteristics of AYAs with chronic primary ITP. Data from patients aged 12 to 25 years with chronic disease at 1 year were extracted from 3 registries (Pediatric and Adult Registry on Chronic ITP, CEREVANCE, and Cytopénies Auto-immunes Registre Midi-Pyrénéen), covering the period from 2004 to 2021. Sustained complete remission off treatment (SCROT) occurring beyond 12 months was defined as platelet count of &gt;100 × 109/L without treatment for at least 12 months, independently of the previous treatment strategy. A total of 427 AYAs (64% female) with chronic primary ITP were included. Clinical information was available for ∼100% of patients at initial diagnosis and at 6- and 12-month follow-ups (FUs); and for 88%, 77%, and 59% at 24, 36, and 48 months, respectively. Over time, clinical features improved gradually, with fewer patients requiring treatment. Throughout the FU period, second-line drug use increased steadily among treated patients, without affecting the need for corticosteroids and IV immunoglobulins. The proportion of new patients achieving SCROT at 24-, 36-, and 48-month FU was 10% (38/375), 9.5% (31/327), and 12% (30/250), respectively, including 23 who underwent splenectomy. AYAs achieving SCROT between 12 and 36 months displayed higher platelet counts in the first year (excluding the initial period) and received fewer IV immunoglobulin treatments beyond 12 months compared with those with ongoing disease.
Biologically synthesized nanoparticles: barley-mediated silver and gold nanoparticles and caged gold nanoplatform for advanced drug delivery system engineering in medicine
Authors: Talaat Muhammad 
Published: October 2024

AbstractThe integration of green synthesis methods and advanced nanostructure designs holds significant promise for the development of innovative nanomaterials with diverse biomedical applications. This commentary delves into the use of barley grains for the eco-friendly synthesis of silver and gold nanoparticles, highlighting their potential as biocompatible agents with potent antibacterial properties. The barley-mediated synthesis approach not only offers a sustainable and cost-effective method for producing these nanoparticles but also underscores their remarkable efficacy against pathogenic bacteria. The barley-mediated approach not only offers a sustainable and cost-effective method for producing biocompatible nanoparticles but also demonstrates remarkable antibacterial efficacy against pathogenic bacteria. By critically evaluating the strengths and potential gaps in this synthesis approach, this commentary emphasizes the importance of integrating green synthesis techniques with advanced nanoparticle applications. Future research directions should aim at optimizing synthesis processes, ensuring enhanced stability and biocompatibility, and exploring the full potential of biologically synthesized nanoparticles in medical treatments and environmental sustainability. This focus on sustainable synthesis and application could pave the way for the next generation of nanomaterials, offering significant advancements in both healthcare and ecological preservation. By examining the strengths, gaps, and potential synergies between these two approaches, this commentary underscores the importance of sustainable synthesis techniques and the development of multifunctional nanoparticles. This integrated approach could lead to the creation of next-generation nanomaterials, offering significant advancements in medical treatments and environmental sustainability.
Characterization of infectious bacterial keratitis in Östergötland County, Sweden: a 10-year retrospective study
Authors: Roth Jenny , Toprak Baris , Somajo Sofia , Macedo Antonio Filipe , Lagali Neil 
Published: October 2024

Abstract
Background
The aim of this study was to characterize bacterial species, aetiology and antibiotic susceptibility connected to bacterial keratitis infections in Östergötland, Sweden.

Methods
Retrospective cross-sectional study based on electronic health records for the period 2010–2019. Records of patients diagnosed with infectious keratitis were screened for microbiology confirmed infectious bacterial keratitis. Bacterial species and their susceptibility to antibiotics were determined from microbiology test results.

Results
One-hundred and ninety patients with lab culture-confirmed infectious bacterial keratitis were included in the analysis. The most frequently found bacterial species were coagulase-negative staphylococci (39%), Staphylococcus aureus (17%) and Cutibacterium acnes (10%). Pseudomonas spp. was the most frequently found Gram-negative bacterial species (7%). Contact lens wear and severely ill/blind eye were the top two aetiologies associated with bacterial keratitis, 22% of the patients with bacterial keratitis were also diagnosed with glaucoma. Most isolates, 157 out of 173, were susceptible to fluoroquinolones, and 145 out of 155 isolates were susceptible to chloramphenicol.

Conclusion
Our results revealed a positive rate of bacterial keratitis of 59% for the samples sent to the laboratory. There was a high susceptibility of the bacterial species to the recommended antibiotics. Our results indicate that it is likely that patients are receiving the correct treatment. Future studies are necessary to monitor changes in antibiotic susceptibility.